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ABSTRACT 
Objective: To develop and validate a new simple, accurate, precise and selective stability-indicating high performance thin layer chromatographic 
(HPTLC) method for simultaneous estimation of Darunavir ethanolate and Ritonavir in combined tablet dosage form as per ICH guidelines.  
Methods: Chromatographic separation of drugs was performed on precoated silica gel aluminium plate 60 F
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254 (10 ×10) with 250 µm thicknesses 
(E. MERCK, Darmstadt, Germany) using a CAMAG Linomat 5 sample applicator (Switzerland). The mobile phase selected was Toluene: Ethyl acetate: 
Methanol (6: 2.5: 1.5, v/v/v) with UV detection at 250 nm. 
Results: The retention factor for Darunavir ethanolate and Ritonavir was found to be 0.29±0.005 and 0.50±0.07. Results were found to be linear in 
the concentration range of 200-1000 ng band-1
Keywords: Darunavir, Ritonavir, HPTLC, Forced degradation. 
for both the drugs. Intra-day variation, as RSD (%), was found to be in the range of 0.45 to 1.54 for 
Darunavir ethanolate and 0.22 to 0.64 for Ritonavir. Interday variation, as RSD (%) was found to be in the range of 0.64 to 1.48 for Darunavir 
ethanolate and 0.13 to 1.24 for Ritonavir. The lower values of % RSD obtained have proved that the method is precise and robust.  
Conclusion: Stability-indicating HPTLC method was developed and validated for simultaneous estimation Darunavir ethanolate and Ritonavir and 
can be used for assessing the stability of Darunavir ethanolate and Ritonavir in bulk drug and pharmaceutical dosage form.  
 
INTRODUCTION  
Darunavir ethanolate (DVR), chemically, [(1R, 5S, 6R)-2, 8-
dioxabicyclo [3.3.0] oct-6-yl] N-[(2S, 3R)-4-[(4-aminophenyl) sulfonyl-
(2-methylpropyl) amino]-3-hydroxy-1-phenyl-butan-2-yl] carbamate 
is a protease inhibitor drug used to treat HIV infection [1]. Ritonavir 
(RTV), 2, 4, 7, 12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-
5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3, 6-dioxo-8, 11-
bis (phenylmethyl)-5-thiazolylmethyl ester [5S-(5R*, 8R*, 10R*, 
11R*)] is a potent cytochrcome P-450 (CYP)3A inhibitor and usually 
used as pharmacokinetic booster for other protease inhibitor [2]. 
Literature survey reveals Spectrophotometric [3, 4], thin layer 
chromatography [5], High Performance Liquid Chromatographic 
(HPLC) [6-13] methods for determination of DVR in bulk and 
pharmaceutical preparations. Analytical methods reported for RTV 
includes HPLC [14-17], LC-MS [18], Densiometry [19-21] and 
spectrophotometry [22] either as single or in combination with 
other drugs. Also reverse phase high performance liquid 
chromatographic method for simultaneous determination of DVR 
and RTV in binary mixture is also reported [23]. 
No reports were found for stability-indicating HPTLC method for 
simultaneous determination of DVR and RTV in tablet dosage form. 
This paper describes simple, precise, accurate and sensitive HPTLC 
method development and validation as well as stability study 
(hydrolysis, oxidation, photo-degradation and thermal degradation) 
as per International Conference on Harmonisation Guidelines [24, 
25]. The developed method would be suitable for simultaneous 
analysis of DVR and RTV in combination without any interference 
from the excipients and it can be successfully applied to estimate the 
amount of DVR and RTV in the formulations by easily available low 
cost materials.  
The method can be used for routine analysis of marketed products 
of DVR and RTV in combined tablet formulation as well as for single 
drug analysis and also can be used for routine analysis of 
pharmaceutical formulations in quality-control laboratories. 
MATERIALS AND METHODS  
Chemicals and reagents 
Analytically pure samples of DVR and RTV were kindly supplied by 
Emcure Pharma Pvt. Ltd. (Pune, India) and Cipla Pvt. Ltd. 
(Kurkumbh, India) respectively. Toluene and Methanol (AR grade) 
were obtained from Thomas Baker Pvt Ltd (Mumbai, India). Ethyl 
acetate was obtained from Loba Chemie Pvt Ltd. (Mumbai, India).  
Instrumentation and Chromatographic conditions 
Chromatographic separation of drugs was performed on precoated 
silica gel aluminium plate 60 F254 (10 ×10) with 250 µm thickness 
(E. MERCK, Darmstadt, Germany) using a CAMAG Linomat 5 sample 
applicator (Switzerland). Samples were applied on the plate as a 
band with 6 mm width using Camag 100 μl sample syringe 
(Hamilton, Switzerland).  
Linear ascending development was carried out in 10 x 10 cm twin 
trough glass chamber (CAMAG, Muttenz, Switzerland) using 
Toluene: Ethyl acetate: Methanol (6: 2.5: 1.5, v/v/v) as mobile phase. 
The optimized chamber saturation time for mobile phase was 15 
min. The length of chromatogram run was 9 cm and development 
time was approximately 15 min. TLC plates were dried in a current 
of air with the help of a hair drier. Densitometric scanning was 
performed on CAMAG thin layer chromatography scanner at 250 nm 
for all developments operated by WINCATS software version 1.4.3. 
The source of radiation utilized was deuterium lamp emitting a 
continuous UV spectrum between 200 to 400 nm.  
Preparation of standard stock solutions 
Standard stock solution of DVR and RTV were prepared by 
dissolving 10 mg of drug in 10 ml of methanol to get concentration 
of 1 mg ml-1 from which 1 ml was further diluted to 10 ml to get 
stock solution of 100 ng µl-1
After chromatographic development bands were scanned over the 
range of 200-400 nm and the spectra was overlain. It was observed 
 of DVR and RTV respectively.  
Selection of detection wavelength 
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that both drugs showed considerable absorbance at 250 nm. So, 250 
nm were selected as the wavelength for detection. 
Analysis of tablet formulation 
The binary mixture of DVR and RTV was prepared in the ratio of 3:1. 
Accurately weighed DVR (300 mg) and RTV (100 mg) was 
transferred to a 100 ml volumetric flask containing 30 ml methanol. 
Common excipients, which are used in the tablet formulation, were 
added in this mixture and the content was sonicated for 15 min. The 
flask was allowed to stand at room temperature for 15 min, and the 
volume was made up to the mark with methanol to obtain the final 
concentration of 3000 ng band-1 for DVR and 1000 ng band-1 for RTV. 
The solution was filtered using Whatman paper No. 41. One ml of the 
above solution was further diluted with methanol to get final 
concentration of 300 ng band-1 for DVR and 100 ng band-1 for RTV. 
Two µl volumes of this solution were applied on TLC plate to obtain 
final concentration of 600 ng band-1 for DVR and 200 ng band-1 for 
RTV. After chromatographic development peak areas of the bands were 
measured at 250 nm and the amount of each drug present in sample was 
estimated from the respective calibration curves. Procedure was 
repeated six times for the analysis of the homogenous sample.  
Stress degradation studies of bulk drug 
The drugs were subjected to stress condition of hydrolysis (acid, 
base), oxidation, photolysis and thermal degradation to provide 
evidence on how stability of drug varies under the influence of 
variety of environmental conditions and to establish specific storage 
conditions, shelf-life and retest period. 
Acid treatment  
1 ml working standard solution of DVR (100 ng µl-1) was mixed with 1 
ml of 0.1 N methanolic HCl and 8 ml of methanol. Solution was kept for 
4 h in dark place. The 4 µl of the resulting solution was applied on TLC 
plate and developed under optimized chromatographic condition. RTV 
was treated in similar manner to DVR. 
Alkali treatment 
1 ml working standard solution of DVR (100 ng µl-1
Neutral hydrolysis 
) was mixed with 1 
ml of 0.1 N methanolic NaOH and 8 ml of methanol. The solution was 
kept for 4 h in the dark place. The 4 µl of the resulting solution was 
applied on TLC plate and developed under optimized chromatographic 
condition. RTV was treated in the similar manner to DVR. 
1 ml working standard solution of DVR (100 ng µl-1
Oxidative degradation  
) was mixed with 
1 ml of water and 8 ml methanol. The solution was kept for 24 h in 
the dark place. The 4 µl of the resulting solution was applied on TLC 
plate and developed under optimized chromatographic condition. 
RTV was treated in the similar manner to DVR. 
1 ml working standard solution of DVR (100 ng µl-1) was mixed with 1 
ml of 6 % solution of H2O2 
Photo-degradation 
and 8 ml of methanol. The solution was 
kept for 4 h in the dark place. The 4 µl of the resulting solution was 
applied on TLC plate and developed under optimized chromatographic 
condition. RTV was treated in the similar manner to DVR. 
Photolytic studies were carried out by exposure of drug to UV light 
up to 200 watt h/m2 and subsequently to fluorescence light 
illumination not less than 1.2 million lux h. Sample was weighed, 
dissolved in methanol to get concentration of 100 ng µl-1
Degradation under dry heat 
. 4 µl of the 
resulting solution was applied to HPTLC.  
Dry heat study was performed by keeping DVR in an oven at 60ºC 
for the period of 2 h. A sample was withdrawn at appropriate times, 
weighed and dissolved in methanol to get the solution of 100 ng µl-1
RESULTS AND DISCUSSION 
. 
4 µl of the resulting solutions was applied to HPTLC. RTV was 
treated in the similar manner to DVR.  
Optimization of chromatographic conditions 
The primary target in developing this stability indicating HPLTC 
method is to achieve the resolution between DVR, RTV and its 
degradation products. The separation was achieved by linear 
ascending development in 10 cm × 10 cm twin trough glass chamber 
using Toluene: Ethyl acetate: Methanol (6: 2.5: 1.5, v/v/v) as mobile 
phase. The optimum wavelength for detection and quantitation used 
was 250 nm. The retention factors for DVR and RTV were found to be 
0.29±0.005 and 0.50±0.07 respectively. Representative densitogram of 
mixed standard solution of DVR and RTV is shown in fig. 1. 
  
 
Fig. 1: Representative densitogram of mixed standard solution of DVR 
(400 ng band-1, Rf = 0.29±0.005) and RTV (400 ng band-1, Rf 
 
Result of forced degradation studies 
Forced degradation study showed the method is highly specific and 
no degradation products were eluted at retention time of drugs. 
Acid treatment  
= 0.50±0.07) 
12 % of DVR and 16 % of RTV degraded in acid condition when 
refluxed for 4 h. However, no additional degradation peaks were 
Deshpande et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 6, 66-71 
68 
seen in the densitogram for RTV. The representative densitogram after acid treatment is shown in fig. 2.  
 
 
(a)    (b) 
Fig. 2: Representative densitogram after acid treatment (a) DVR with degradation product at Rf 0.72 and (b) RTV 
 
Alkali treatment 
22 % of degradation of DVR was observed in alkaline condition while 25 
% degradation of RTV was observed with degradation products. The 
representative densitogram after alkali treatment is shown in fig. 3. 
Oxidative degradation  
17 % degradation was observed for DVR when treated with 6 % 
H2O2 
 
(a)     (b) 
Fig. 3: Representative densitogram after alkali treatment (a) DVR with degradation product at Rf 0.02, 0.39 and (b) RTV with degradation 
product at Rf 0.02, 0.05, 0.89 
 
while RTV exhibited 26 % degradation. The representative 
densitogram after oxidative degradation is shown in fig. 4. 
 
 
(a)     (b) 
Fig. 4: Oxidative degradation densitogram of (a) DVR and (b) RTV with degradation product at Rf 0.15 
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Neutral hydrolysis 
16 % degradation was observed for DVR in neutral condition when 
refluxed for 24 h with degradation peak at Rf 0.57 while 11 % of 
degradation was observed for RTV. The representative densitogram 
after neutral degradation is shown in fig. 5. 
Photo degradation studies  
DVR exhibited 10 % and 15 % of degradation when exposed to 
ultraviolet light (200 Watt h/m2
Dry degradation studies 
) and fluorescence light (1.2 million 
lux h) and RTV shown 9 % and 12 % of degradation when exposed 
to fluorescence light (1.2 million lux h). The representative 
densitogram after photo degradation is shown in fig. 6. 
21 % and 19 % of degradation was observed for DVR and RTV when 
the powdered drug substances were exposed to dry heat at 60º C for 
24 h. The representative densitogram obtained from sample 
subjected to dry heat is shown in fig. 7. 
 
 
(a)     (b) 
Fig. 5: Neutral degradation densitogram of (a) DVR along with its degradation product (Rf 0.57) and (b) RTV 
 
 
(a)    (b) 
Fig. 6: Photo degradation densitogram of (a) DVR and (b) RTV 
 
 
(a)     (b) 
Fig. 7: Densitogram obtained from sample subjected to dry heat (a) DVR and (b) RTV 
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The results of the stress testing of the drugs carried out revealed that 
the degradation products were formed in hydrolytic (acid and base), 
oxidative conditions. The developed method is able to separate the 
peaks of active pharmaceutical ingredients from their degradation 
products formed under various stress conditions and excipients used 
in tablet dosage forms and hence, it can be used for monitoring quality 
during stability studies of pharmaceutical preparations. 
Peak purity results greater than 990 indicate that DVR and RTV 
peaks are homogeneous in all stress conditions tested. The 
unaffected assay of DVR and RTV in the tablet confirms the stability 
indicating power of the method. The forced degradation studies data 
are summarized in table 1. 
Method validation  
The method was validated for linearity, accuracy, intra-day and 
inter-day precision and robustness, in accordance with ICH 
guidelines [24, 25]. 
Preparation of calibration curve  
The standard stock solutions of DVR and RTV (100 ng µl-1 each) 
were applied by overspotting on TLC plate in the range of 2, 4, 6, 8, 
10, 12 and 14 µl. Straight-line calibration graphs were obtained in 
the concentration range 200-1400 ng band-1
Stress conditions/duration  
 
 for both the drugs with 
the high correlation coefficient>0.998. 
 
Table 1: Data of forced degradation studies of DVR and RTV 
 DVR  RTV 
(%) Degradation (%) Degradation 
Acidic/0.1 N HCl/Reflux for 4 h 12 16 
Alkaline/0.1 N NaOH/Reflux for 4 h 22 25 
Oxidative/6 % H2O2 17 /Reflux for 24 h 26 







Fluorescence/1.2 million lux h 15 12 
Dry heat/60ºC/24 h 21 19 
 
Precision 
Set of three different concentrations in three replicates of mixed 
standard solutions of DVR and RTV were prepared. All the solutions 
were analyzed on the same day in order to record any intraday 
variations in the results. Intra-day variation, as RSD (%), was found 
to be in the range of 0.45 to 1.54 for DVR and 0.22 to 0.64 for RTV. 
For Inter day variation study, three different concentrations of the 
mixed standard solutions in linearity range were analyzed on three 
consecutive days. Interday variation, as RSD (%) was found to be in 
the range of 0.64 to 1.48 for DVR and 0.13 to 1.24 for RTV. The lower 
values of % RSD obtained have proved that the developed method is 
precise. 
Limit of detection (LOD) and Limit of quantitation (LOQ) 
LOD and LOQ were calculated as 3.3 σ/S and 10 σ/S, respectively; 
where σ is the standard deviation of the response (y-intercept) and 
S is the slope of the calibration plot. The LOD of DVR and RTV was 
found 65 ng band-1 and 30 ng band-1, respectively. The LOQ of RTV 
and ATV was 192 ng band-1 and 91 ng band-1
Recovery studies 
, respectively.  
To check accuracy of the method, recovery studies were carried out 
by adding standard drug to sample at three different levels 80, 100 
and 120 %. Basic concentration of sample chosen was 300 ng band-1 
of DVR and 100 ng band-1
Specificity 
 of RTV. The drug concentrations were 
calculated from respective linearity equation. The results of 
recovery studies indicated that the method is accurate for 
estimation of drugs in tablet dosage form. The results obtained are 
shown in table 2. 
The specificity of the method was ascertained by peak purity 
profiling studies. The peak purity values were found to be more than 
991, indicating the no interference of any other peak of degradation 
product, impurity or matrix. 
 
Table 2: Recovery studies of DVR and RTV 




Total amount found 
(ng band) -1
 




600 480 1078.41 99.81 0.65 
600 600 1186.38 98.80 0.62 
600 720 1312.75 99.43 0.95 
 
RTV 
200 160 4479.77 101.10 0.82 
200 200 6020.78 99.33 0.52 
200 240 7535.32 99.61 1.48 
*Average of three determinations  
 
Table 3: Robustness data in terms of peak area (% RSD) 
S. No. Parameter (% RSD)* 
DVR RTV 
1 Mobile phase saturation (±10 %) 0.70 0.50 
2 Wavelength 1.00 0.78 
3 Time from application to development (0, 10, 20, and 30 min) 0.54 0.52 
4 Development to scanning 
(0, 30, 60, and 90 min) 
1.00 0.61 
*Average of three determinations  
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Robustness studies 
Robustness of the method was determined by carrying out the 
analysis under conditions during which mobile phase saturation 
time, wavelength, time from application to development and from 
development to scanning were altered and the effect on the area of 
the drug was noted. When deliberate variations were made to the 
method conditions, there were no marked changes in 
chromatographic behaviour, indicating the method is robust. The 
results are given in table 3. 
CONCLUSION 
The developed method is stability indicating and can be used for 
assessing the stability of DVR and RTV in bulk drug and 
pharmaceutical dosage form. The developed method is accurate, 
precise, specific and robust. 
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